Sanofi-Aventis SA (SASY.PA) has agreed in principle to acquire Genzyme Corp (GENZ.O) for $19.2 billion in cash plus future payments based on the performance of an experimental drug, according to a source with knowledge of the talks. Under the agreement, Genzyme investors will receive $74 per share in cash plus a contingent value right, or CVR, tied to Genzyme's experimental multiple sclerosis drug. The value of the CVR could not immediately be established. The deal is expected to be announced by Wednesday morning, the source said. The two companies' boards are expected to vote shortly.
Source
